Merck initiates Phase III study of adalimumab biosimilar MSB11022, in Chronic Plaque Psoriasis

March 3, 2016 11:44 AM

merck_logo

Merck KGaA announced the initiation of a global phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis.

“With the first patient now treated in our adalimumab biosimilar candidate study, we are moving closer to expanding access to affordable, high quality biologics for people living with serious diseases,” said Michael Soldan, Head of the Biosimilar Business of Merck. “At the same time, this milestone supports our broader healthcare strategy to complement our innovative R&D pipeline with biosimilars that serve as important therapeutic options for patients in need.”

The AURIEL-Psoriasis (PsO) study is a randomized, double-blind, active-controlled trial evaluating the efficacy, safety and immunogenicity of Merck’s adalimumab biosimilar candidate MSB11022 compared with the brand Humira® (adalimumab) in patients with moderate to severe chronic plaque psoriasis. Humira is marketed globally by AbbVie, Inc.

The study is expected to recruit approximately 400 patients across Europe, Asia and North and Central America.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!